ERAS方案下晚期卵巢癌一线治疗期间静脉血栓栓塞风险
本研究回顾性分析230例接受初次或间歇性肿瘤细胞减灭术的晚期上皮性卵巢癌患者,所有患者均纳入ERAS方案并接受术后28天VTE预防。诊断后6个月内VTE累积发生率为6.1%(95% CI 4.3-8.8%),1年内为8.5%(6.2-11.4%)。估计失血量和VTE病史与VTE独立相关。
要点
- ERAS方案下术后30天内VTE发生率为2.2%(5/230)。
- 一线治疗期间总体VTE发生率为1/16(38/230)。
- 估计失血量(aHR 1.22)和VTE病史(aHR 7.06)是独立危险因素。
核心结论
- 实施ERAS方案后,术后30天内仅1/46患者发生VTE,但一线治疗期间总体VTE发生率为1/16。
- 需探索在新辅助化疗和监测期间进一步降低VTE风险的策略。
研究设计与样本
- 回顾性病历审查,纳入2017年3月至2019年9月接受初次或间歇性肿瘤细胞减灭术的FIGO IIIA-IVB期上皮性卵巢癌、输卵管癌或原发性腹膜癌患者230例。
- 所有患者均纳入ERAS方案,包括术后28天VTE预防。
主要发现
- 38例患者在研究期间发生VTE,其中诊断时13例(5.7%),新辅助化疗期间6例(3.9%),术后30天内5例(2.2%),术后30天至6个月5例(2.2%),6个月后9例(3.9%)。
- 诊断后6个月内VTE累积发生率为6.1%(95% CI 4.3-8.8%),1年内为8.5%(6.2-11.4%)。
- 估计失血量(调整HR 1.22 [95% CI 1.09-1.36],p=0.001)和VTE病史(调整HR 7.06 [95% CI 2.34-21.29],p=0.001)与VTE独立相关。
临床怎么用
- ERAS方案下术后30天内VTE风险较低,但仍需关注新辅助化疗和随访期间的VTE风险。
- 对估计失血量较高或有VTE病史的患者应加强VTE风险评估与预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine incidence and risk factors for VTE for patients with advanced epithelial ovarian cancer undergoing first-line therapy, including cytoreductive surgery, on an Enhanced Recovery After Surgery (ERAS) protocol. METHODS: Medical records were reviewed for patients with FIGO stage IIIA-IVB epithelial ovarian, fallopian tube, or primary peritoneal cancer undergoing primary or interval cytoreductive surgery from March 2017 through September 2019. All patients were enrolled on an ERAS protocol, including 28-day postoperative VTE prophylaxis. Demographic information, medical history, perioperative characteristics, and ERAS compliance were evaluated using univariate and multivariate models. RESULTS: Of 230 patients undergoing cytoreductive surgery via laparotomy, 155 received neoadjuvant chemotherapy and 75 received primary cytoreduction. 38 patients had a VTE during the study period. 13 events (5.7%) were identified at time of diagnosis, 6 (3.9%) during neoadjuvant chemotherapy, 5 (2.2%) within 30 days after surgery, 5 (2.2%) between 30 days and 6 months after surgery, and 9 (3.9%) after the 6-month window. The cumulative incidence of VTE was 6.1% (95% CI, 4.3-8.8%) within 6 months after diagnosis and 8.5% (6.2-11.4%) within 1 year after diagnosis. Estimated blood loss (adjusted HR 1.22 [95% CI, 1.09-1.36], p = 0.001) and history of VTE (7.06 [2.34-21.29], p = 0.001) were independently associated with VTE. CONCLUSION: With implementation of an ERAS protocol, only 1 in 46 patients experienced a VTE within 30 days after surgery. However, overall VTE occurred in 1 in 16 patients during first-line therapy. Strategies to further reduce VTE risk, especially during neoadjuvant chemotherapy and surveillance, should be investigated.
引用
- Li S, Bercow AS, Falzone M, et al. Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol. Gynecol Oncol. 2021. PMID: 34092412. doi:10.1016/j.ygyno.2021.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。